Tenax Therapeutics, Inc.
TENX
$1.83
-$0.01-0.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 50.35% | 106.05% | 249.49% | 258.13% | 194.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.79% | 128.87% | 189.24% | 203.93% | 168.78% |
| Operating Income | -95.79% | -128.87% | -189.24% | -203.93% | -168.78% |
| Income Before Tax | -106.03% | -139.18% | -198.82% | -197.55% | -150.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -106.03% | -139.18% | -198.82% | -197.55% | -150.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.03% | -139.18% | -198.82% | -197.55% | -150.42% |
| EBIT | -95.79% | -128.87% | -189.24% | -203.93% | -168.78% |
| EBITDA | -- | -- | -- | 53.04% | 8.58% |
| EPS Basic | -59.74% | 43.47% | 74.82% | 92.88% | 95.87% |
| Normalized Basic EPS | -59.73% | 43.47% | 74.82% | 92.88% | 95.87% |
| EPS Diluted | -59.74% | 43.47% | 74.82% | 92.88% | 95.87% |
| Normalized Diluted EPS | -59.73% | 43.47% | 74.82% | 92.88% | 95.87% |
| Average Basic Shares Outstanding | 33.29% | 74.17% | 162.97% | 513.68% | 3,413.47% |
| Average Diluted Shares Outstanding | 33.29% | 74.17% | 162.97% | 513.68% | 3,413.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |